| Bioactivity | Haloperidol is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic. | ||||||||||||
| In Vivo | Haloperidol (1 mg) intra-arterially attenuates the dopamine-induced pancreatic secretion. Haloperidol (3 mg) completely inhibits the action of 10 μg of dopamine in the pancreas of the dogs[1]. Haloperidol (10 mg/kg) as well as chlorpromazine (CPZ, 15 mg/kg) blocks mescaline-induced altered behavior within 7 to 10 minutes when injected into the mice 45 minutes after 50 mg/kg (2 µc) of mescaline. Haloperidol has no effect on mescaline disappearance[2]. | ||||||||||||
| Name | Haloperidol | ||||||||||||
| CAS | 52-86-8 | ||||||||||||
| Formula | C21H23ClFNO2 | ||||||||||||
| Molar Mass | 375.86 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Furuta Y, et al. Effects of enzyme inhibitors of catecholamine metabolism and of haloperidol on the pancreatic secretion induced by L-DOPA and by dopamine in dogs. Br J Pharmacol. 1973 Jan;47(1):77-84 [2]. Shah NS, et al. Effects of chlorpromazine and haloperidol on the disposition of mescaline-14C in mice. J Pharmacol Exp Ther. 1973 Aug;186(2):297-304 |